An evaluation of pyrisuccideanol maleate (Nadex) in the treatment of mild to moderate depression in patients aged 55 years and over, presenting in general practice.
D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D013386:Succinates / Q000009:adverse effects / Q000627:therapeutic use
D000928:Antidepressive Agents; D011725:Pyridines; D013386:Succinates; C009656:pyrisuccideanol